NASDAQ:CYCN - Cyclerion Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 559.13 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.77
▼ -0.2 (-10.15%)

This chart shows the closing price for CYCN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cyclerion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYCN

Analyst Price Target is $11.67
▲ +559.13% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cyclerion Therapeutics in the last 3 months. The average price target is $11.67, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 559.13% upside from the last price of $1.77.

This chart shows the closing price for CYCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Cyclerion Therapeutics. This rating has held steady since May 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2021Truist SecuritiesInitiated CoverageBuy$14.00Medium
10/20/2021TruistInitiated CoverageBuy$14.00High
9/24/2021Cantor FitzgeraldInitiated CoverageOverweight$7.00High
6/3/2019Credit Suisse GroupInitiated CoverageNeutral ➝ NeutralHigh
(Data available from 12/5/2016 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cyclerion Therapeutics logo
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $1.77
Low: $1.75
High: $1.97

50 Day Range

MA: $2.67
Low: $1.77
High: $3.44

52 Week Range

Now: $1.77
Low: $1.75
High: $6.90

Volume

327,084 shs

Average Volume

495,433 shs

Market Capitalization

$76.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Cyclerion Therapeutics?

The following Wall Street analysts have issued reports on Cyclerion Therapeutics in the last twelve months: Cantor Fitzgerald, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for CYCN.

What is the current price target for Cyclerion Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Cyclerion Therapeutics in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 559.1%. Truist has the highest price target set, predicting CYCN will reach $14.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $7.00 for Cyclerion Therapeutics in the next year.
View the latest price targets for CYCN.

What is the current consensus analyst rating for Cyclerion Therapeutics?

Cyclerion Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYCN will outperform the market and that investors should add to their positions of Cyclerion Therapeutics.
View the latest ratings for CYCN.

What other companies compete with Cyclerion Therapeutics?

How do I contact Cyclerion Therapeutics' investor relations team?

Cyclerion Therapeutics' physical mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company's listed phone number is (857) 327-8778 and its investor relations email address is [email protected] The official website for Cyclerion Therapeutics is www.cyclerion.com.